GlassScriptPhysician profile
Craig Orofino
NPI 1922268887
$42,767.47
in general payments reported to CMS, 2019-2025
34 companies · $7,893 in 2025
The $7,893 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,799 · 2022: $13K · 2023: $9,516 · 2024: $8,030 · 2025: $7,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,638.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,500.00 |
| Education | $300.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24,405.92 | 2021-2025 | |
| Janssen Biotech, INC. | $2,747.24 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $2,708.05 | 2021-2025 | Evenity, Tavneos, Otezla |
| Horizon Therapeutics Plc | $2,653.74 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $2,081.18 | 2021-2025 | Acthar |
| Incyte Corporation | $1,002.19 | 2022-2025 | Opzelura, Opzelura |
| Ucb, INC. | $944.58 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $792.66 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $761.61 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $570.53 | 2021-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $522.96 | 2021-2025 | |
| Glaxosmithkline, LLC. | $477.37 | 2021-2025 | Benlysta, Nucala |
| Astrazeneca Pharmaceuticals LP | $429.90 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $309.21 | 2021-2024 | Taltz, Zepbound |
| Pacira Therapeutics, INC. | $276.93 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $275.57 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.30 | 2021-2025 | Spevigo, Cyltezo |
| Janssen Scientific Affairs, LLC | $249.77 | 2021-2022 | |
| Organon LLC | $219.57 | 2023-2025 | Hadlima, Renflexis |
| Aurinia Pharma U.S., INC. | $168.63 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $168.12 | 2021-2025 | Actemra |
| Neurocrine Biosciences, INC. | $125.00 | 2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $117.92 | 2025 | Tremfya |
| Octapharma USA, INC. | $93.55 | 2024-2025 | Octagam Immune Globulin (Human) |
| Genzyme Corporation | $80.61 | 2025 | |
| Radius Health, INC. | $77.84 | 2021-2025 | Tymlos |
| Teva Pharmaceuticals USA, INC. | $56.89 | 2021-2023 | Truxima |
| Ferring Pharmaceuticals INC. | $39.84 | 2021 | |
| Alexion Pharmaceuticals, INC. | $31.46 | 2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $27.19 | 2021 | |
| Bioventus LLC | $24.23 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $20.21 | 2025 | |
| Sandoz INC. | $19.00 | 2024 | Hyrimoz |
| Arbor Pharmaceuticals, INC. | $18.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Orofino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.